Repare Therapeutics Overview
- Year Founded
-
2016
- Status
-
Acquired/Merged
- Employees
-
150
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$78.7M
Repare Therapeutics General Information
Description
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.
Contact Information
Website
www.reparerx.com(Operating Subsidiary)
Corporate Office
- 7171 Frederick-Banting
- Building 2
- Saint-Laurent, Quebec H4S 1Z9
- Canada
Corporate Office
- 7171 Frederick-Banting
- Building 2
- Saint-Laurent, Quebec H4S 1Z9
- Canada
Repare Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Merger/Acquisition | 28-Jan-2026 | $78.7M | Completed | Generating Revenue | ||
| 6. 2PO | 01-Nov-2021 | Completed | Generating Revenue | |||
| 5. IPO | 19-Jun-2020 | Completed | Pre-Clinical Trials | |||
| 4. Early Stage VC | 29-May-2020 | Completed | Pre-Clinical Trials | |||
| 3. Early Stage VC (Series B) | 04-Sep-2019 | Completed | Startup | |||
| 2. Early Stage VC (Series A) | 22-Jun-2017 | $68M | $68M | Completed | Startup | |
| 1. Accelerator/Incubator | Completed | Startup |
Repare Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A |
Repare Therapeutics Comparisons
Industry
Financing
Details
Repare Therapeutics Competitors (85)
One of Repare Therapeutics’s 85 competitors is ImmunityBio, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| ImmunityBio | Formerly VC-backed | San Diego, CA | ||||
| Ayala Pharmaceuticals | Corporation | Wilmington, DE | ||||
| Sorrento Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Intellia Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Sangamo Therapeutics | Formerly VC-backed | Richmond, CA |
Repare Therapeutics Patents
Repare Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026125935-A1 | Methods of treating cancers having fbxw7 mutations | Pending | 09-Dec-2024 | ||
| WO-2026003756-A1 | Methods of determining pharmacodynamic activity and treatment efficacy | Pending | 25-Jun-2024 | ||
| WO-2025255237-A1 | Use of atr inhibitors in combination with radioligand therapy for the treatment of cancer | Pending | 04-Jun-2024 | ||
| WO-2025177244-A1 | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use | Pending | 22-Feb-2024 | ||
| WO-2025169150-A1 | Crystalline forms, crystalline salt forms, compositions containing the same, and methods of using the same | Pending | 09-Feb-2024 | A61P35/00 |
Repare Therapeutics Signals
Repare Therapeutics Former Investors (15)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Amplitude Ventures | Venture Capital | Minority | ||
| BDC Capital | Growth/Expansion | Minority | ||
| BVF Partners | Hedge Fund | Minority | ||
| Bristol-Myers Squibb | Corporation | Minority | ||
| Celgene | Corporation | Minority |
Repare Therapeutics Investments (1)
Repare Therapeutics’s most recent deal was a Early Stage VC with DCx Biotherapeutics. The deal was made on 01-Jan-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| DCx Biotherapeutics | 01-Jan-2025 | Early Stage VC | Biotechnology |
Repare Therapeutics ESG
Risk Overview
Risk Rating
Updated December, 31, 2022
31.93 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 16,216
Rank
Percentile
Pharmaceuticals
Industry
of 921
Rank
Percentile
Pharmaceuticals
Subindustry
of 452
Rank
Percentile
Repare Therapeutics FAQs
-
When was Repare Therapeutics founded?
Repare Therapeutics was founded in 2016.
-
Where is Repare Therapeutics headquartered?
Repare Therapeutics is headquartered in Saint-Laurent, Canada.
-
What is the size of Repare Therapeutics?
Repare Therapeutics has 150 total employees.
-
What industry is Repare Therapeutics in?
Repare Therapeutics’s primary industry is Drug Discovery.
-
Is Repare Therapeutics a private or public company?
Repare Therapeutics is a Private company.
-
What is the current valuation of Repare Therapeutics?
The current valuation of Repare Therapeutics is .
-
What is Repare Therapeutics’s current revenue?
The current revenue for Repare Therapeutics is .
-
How much funding has Repare Therapeutics raised over time?
Repare Therapeutics has raised $520M.
-
Who are Repare Therapeutics’s investors?
Amplitude Ventures, BDC Capital, BVF Partners, Bristol-Myers Squibb, and Celgene are 5 of 15 investors who have invested in Repare Therapeutics.
-
Who are Repare Therapeutics’s competitors?
ImmunityBio, Ayala Pharmaceuticals, Sorrento Therapeutics, Intellia Therapeutics, and Sangamo Therapeutics are some of the 85 competitors of Repare Therapeutics.
-
When was Repare Therapeutics acquired?
Repare Therapeutics was acquired on 28-Jan-2026.
-
Who acquired Repare Therapeutics?
Repare Therapeutics was acquired by XenoTherapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process